ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,030Medicare Part D Prescriptions Filled, Including Refills

Rank: 74 out of 559

$344K Total Retail Price of All Prescriptions

Rank: 92 out of 559

360 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
18% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Mexico
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

7% of this provider’s 360 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 6,442 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$49 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Mexico
SIMVASTATIN 419 389 1 3
LEVOTHYROXINE SODIUM 408 368 2 2
OMEPRAZOLE 346 297 3 4
AMLODIPINE BESYLATE 293 268 4 6
METFORMIN HCL 217 212 5 5
LISINOPRIL 206 195 6 1
LISINOPRIL-HYDROCHLOROTHIAZIDE 184 184 7 18
FLUOXETINE HCL 175 155 8 37
ALENDRONATE SODIUM 171 167 9 13
GABAPENTIN 121 102 10 9
DONEPEZIL HCL 119 119 11 36
CRESTOR 115 101 12 33
FUROSEMIDE 113 100 13 11
ATENOLOL 111 106 14 15
TAMSULOSIN HCL 109 107 15 25
DIOVAN HCT 103 88 16 134
LOVASTATIN 94 86 17 10
ALLOPURINOL 88 83 18 34
FLUTICASONE PROPIONATE 87 68 19 22
CITALOPRAM HBR 85 84 20 21
ACETAMINOPHEN-CODEINE 83 79 S3 21 83
HYDROCHLOROTHIAZIDE 81 79 22 8
METOPROLOL TARTRATE 81 78 22 12
TRIAMTERENE-HCTZ 72 71 24 47
AZITHROMYCIN 71 71 25 39
METOPROLOL SUCCINATE 70 70 26 16
PROAIR HFA 68 63 27 29
LOSARTAN POTASSIUM 64 57 28 14
DIOVAN 64 62 28 55
TRAZODONE HCL 64 45 28 28
PAROXETINE HCL 58 52 31 48
BETAMETHASONE VALERATE 57 57 32 202
LOSARTAN-HYDROCHLOROTHIAZIDE 56 53 33 52
GEMFIBROZIL 56 45 33 71
AMITRIPTYLINE HCL 54 54 R 35 58
ATORVASTATIN CALCIUM 51 51 36 20
OXYBUTYNIN CHLORIDE 51 51 36 62
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 12, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.